Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

SUPNBullishM&Anews

High materiality9/10

Supernus-Indivior Merger Creates CNS Leader with $2.2B Revenue, 2026 Close

Aug 3, 2026, 6:33 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

All-stock deal with clear synergies and a credible path to higher pro forma revenue/EBITDA can re-rate SUPN on scale and cash-flow potential; risk includes integration challenges and share dilution effects on existing SUPN holders.

AI summary

What happened, with direct paths to the underlying reporting

Supernus and Indivior announced a tax-free all-stock merger of equals to form a diversified CNS biopharma with pro forma revenue of $2.2 billion and EBITDA of $888 million. The deal targets $125 million in annual cost synergies and strengthens the balance sheet with leverage under 1x, while appointing leadership from both sides; closing is targeted for Q4 2026.

All-stock merger of equals creates a CNS-focused platform; pro forma revenue $2.2B.
Merger targets $125M annual cost synergies and stronger financial flexibility.
New entity named Supernus, Inc.; Indivior to own ~56.5% post-close.
Close expected in Q4 2026; leadership to include Jack Khattar as CEO.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Supernus-Indivior Merger Creates CNS Leader with $2.2B Revenue, 2026 Close

Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial

ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug